Feb 27, 2026 KOL Roundtable on Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia Feb 12, 2026 IGALMI Commercial Opportunity in the At-Home Setting for Bipolar Disorders and Schizophrenia Dec 08, 2025 KOL Video -Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions Nov 17, 2025 BioXcel Therapeutics Corporate Presentation Nov 10, 2025 BXCL501 (Sublingual Dexmedetomidine) for Treatment of Agitation Associated With Bipolar Disorder or Schizophrenia in the Home Setting: a Phase 3 Study Aug 27, 2025 SERENITY At-Home Pivotal Phase 3 Safety Trial Topline Results Presentation Aug 11, 2025 BXCL501 BP SCHZ Agitation Commercial Overview Apr 10, 2024 Acute Treatment of Agitation Associated with Alzheimer’s Dementia: TRANQUILITY Program Dec 12, 2023 Virtual Neuroscience R&D Day Presentation Oct 10, 2023 BXCL701 / KEYTRUDA® in Small Cell Neuroendocrine Prostate Cancer Jun 29, 2023 Acute Treatment of Agitation in Alzheimer’s Disease: TRANQUILITY II Summary May 25, 2023 SERENITY III Part 1 Topline Results Mar 02, 2023 Novel Treatment for Agitation in Neuropsychiatric Conditions Feb 21, 2023 BXCL701 KOL Day Presentation Feb 13, 2023 BXCL701 Full Data Results From Phase 2 Trial in Rare, Aggressive Form of Prostate Cancer—SCNC Jan 11, 2023 41th Annual J.P. Morgan Healthcare Conference Presentation Oct 18, 2022 IGALMI Commercial Day Presentation Apr 06, 2022 IGALMI™ Approval Presentation Sep 23, 2021 R&D Day Mar 03, 2021 Phase 1b/2 TRANQUILITY Trial – Program Update Jul 20, 2020 SERENITY I & II Phase 3 Trials Topline Results Sep 10, 2025 SERENITY At-Home Pivotal Phase 3 Safety Trial Topline Results
Feb 27, 2026 KOL Roundtable on Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
Feb 12, 2026 IGALMI Commercial Opportunity in the At-Home Setting for Bipolar Disorders and Schizophrenia
Dec 08, 2025 KOL Video -Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Nov 10, 2025 BXCL501 (Sublingual Dexmedetomidine) for Treatment of Agitation Associated With Bipolar Disorder or Schizophrenia in the Home Setting: a Phase 3 Study
Feb 13, 2023 BXCL701 Full Data Results From Phase 2 Trial in Rare, Aggressive Form of Prostate Cancer—SCNC
